Verekitug + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Asthma
Conditions
Severe Asthma
Trial Timeline
May 21, 2025 → Sep 1, 2027
NCT ID
NCT06966479About Verekitug + Placebo
Verekitug + Placebo is a phase 2 stage product being developed by Upstream Bio for Severe Asthma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06966479. Target conditions include Severe Asthma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06966479 | Phase 2 | Recruiting |
Competing Products
20 competing products in Severe Asthma